The short version of human growth hormone fits in a sentence. The long version — which is the one that helps — is below.
Reviewed 2026-07-13. Anything still debated is marked as such rather than presented as settled.
AOD-9604 has been investigated primarily as a potential treatment for obesity and related metabolic conditions. Early laboratory work examined its effects on fat cells, and later studies moved into animal models and human clinical trials. Some trials reportedly reached Phase II, but the program did not lead to an approved medicine. Published summaries often note that weight-loss results were modest or inconsistent. The full trial data are not all publicly available in detail.
Regulatory treatment of AOD-9604 has varied. In sports anti-doping, the peptide became widely discussed during a 2013 investigation into an Australian professional sports club. Authorities at the time debated whether it fell under prohibitions on growth hormone and related substances. Later clarifications and updated lists have addressed the compound in different ways. Anyone seeking current status should consult the latest applicable rules, and commercial supply for human use is not authorized in major markets.
Research interest in AOD-9604 often focuses on whether it can influence lipid metabolism without the growth-promoting or glucose-related effects of full-length hGH. This question remains unresolved, and findings depend on model, dose, and measurement method. Some reviews treat the peptide as a historical obesity candidate rather than an active therapeutic. Others cite it in discussions of peptide fragments, metabolic signaling, and performance-enhancing substances. Clear conclusions are limited by the small number of rigorous, independent human studies.
Regulatory bodies have taken different approaches to AOD-9604. It is not approved as a prescription medicine by major agencies such as the U.S. Food and Drug Administration or the European Medicines Agency. In sport, the World Anti-Doping Agency prohibits peptide hormones, growth factors, and related substances, and AOD-9604 has been treated as a prohibited substance. These regulatory decisions reflect concerns about safety, efficacy, and potential misuse rather than proof of benefit.
Research on AOD-9604 also examines how the peptide is measured in biological samples. Analytical methods may include liquid chromatography coupled with mass spectrometry, immunoassays, or both. Detection can be challenging because the peptide is small and may be present at low concentrations. Published methods vary in sensitivity and specificity, so comparative interpretation requires attention to validation details. The presence of related hGH fragments can complicate identification in some matrices.
AOD-9604 has been investigated mainly in the context of body fat and metabolic endpoints. Some early animal and small human studies reported changes in fat mass or lipid markers, but findings were not uniform. Larger, well-controlled trials that would establish efficacy are lacking in the public literature. As a result, claims about weight loss or metabolic benefit remain investigational rather than established. The distinction between a research finding and a proven clinical outcome is central to discussing this peptide.
| Property | Value | Notes |
|---|---|---|
| Primary research area | Obesity and metabolic regulation | Studied in cell, animal, and human models |
| Highest reported trial phase | Phase II | Public summaries describe mixed results |
| Common route in trials | Subcutaneous injection | Typical for peptide therapeutics |
| Regulatory example | 2013 Australian anti-doping review | Classification was debated at the time |
| Approval status | Not approved as a human medicine | Status can change by jurisdiction |
A central uncertainty is whether observed metabolic changes translate into meaningful clinical benefits. Study designs vary in dose, duration, and participant characteristics, making comparisons difficult. Independent replication is limited, and the field lacks consensus on optimal endpoints or treatment duration. Ongoing or future studies may clarify mechanism and effect size, but current evidence does not establish a clear therapeutic role. Researchers often call for larger, longer, and better-controlled trials, while questions remain about which patient groups might respond.
Proposed mechanism focuses on lipolysis, the breakdown of stored triglycerides into free fatty acids and glycerol. AOD-9604 is thought to act on adipose tissue without stimulating appetite or affecting blood sugar in the same way as growth hormone. Laboratory studies report increased fat oxidation in some models. The precise receptor interactions and signaling pathways remain incompletely characterized. Researchers have proposed that the peptide may influence fat mobilization through pathways distinct from the full hormone.
Research has examined whether the peptide affects fat mass independently of growth hormone's other actions. Early animal studies suggested reductions in body fat, but species differences and small sample sizes limit interpretation. Human studies have generally been short and have not consistently shown large effects. Some trials measured body composition, lipid profiles, and safety parameters, but the overall picture is one of suggestive yet inconclusive metabolic activity. Findings vary across study populations and protocols.
Several names appear in scientific and commercial settings. AOD9604 and AOD-9604 are development codes used interchangeably, while hGH fragment 176-191 describes the same region. The peptide includes a disulfide bond between two cysteine residues, which helps shape its three-dimensional structure. Different suppliers may provide acetate or other salt forms, and purity can vary. These differences matter because analytical tests and biological assays can respond to the specific form being studied.
Early interest in AOD-9604 centered on whether a fragment of human growth hormone could influence fat metabolism without the broader effects of the full hormone. Cell and animal studies reported changes in fat storage and breakdown. Human trials followed, but the results were not strong enough to secure regulatory approval. The compound remains available for laboratory research, and its clinical potential is still described as uncertain. Studies continue to examine its activity and safety profile.
=== Circadian rhythm sleep disorders === Melatonin receptor agonists like melatonin and tasimelteon are considered to be effective in regulating sleep–wake cycles and in the treatment of circadian rhythm sleep disorders like delayed sleep phase disorder. Ramelteon has been assessed in only a few studies in the treatment of circadian rhythm sleep disorders, including jet lag disorder, shift work disorder, and non-24-hour sleep–wake disorder. These studies have been of varying quality and their findings in terms of effectiveness have been mixed. Ramelteon is approved only for treatment of insomnia and is not approved for treatment of circadian rhythm sleep disorders. It was previously under development for treatment of circadian rhythm sleep disorders, but development for these indications was discontinued. Some clinical trials since 2020 have found that dosages much lower than the standard 8 mg tablet may be more effective at advancing the circadian rhythm.
Mycosporine-like amino acids (MAAs) are small secondary metabolites produced by organisms that live in environments with high volumes of sunlight, usually marine environments. The exact number of compounds within this class of natural products is yet to be determined, since they have only relatively recently been discovered and novel molecular species are constantly being discovered; however, to date their number is around 30. They are commonly described as "microbial sunscreens" although their function is believed not to be limited to sun protection. MAAs represent high potential in cosmetics, and biotechnological applications. Indeed, their UV-absorbing properties would allow to create products derived from natural photoprotectors, potentially harmless to the environment and efficient against UV damage.
== In biology == The best-studied 2-Carboxy-D-arabinitol-1-phosphate phosphatase is the enzyme that inactivates the RuBisCO inhibitor 2-carboxy-D-arabinitol-1-phosphate (CA1P). When light levels are high, the inactivation occurs after CA1P has been released from RuBisCO by RuBisCO activase. As CA1P is present in many but not all plants, CA1P-mediated regulation of RuBisCO is not universal for all photosynthetic life. Amino acid sequences of the CA1Pase enzymes from wheat, French bean, tobacco, and Arabidopsis thaliana reveal that the enzymes contain 2 different domains, indicating that it is a multifunctional enzyme. CA1Pase enzyme activity varies between different species due to their regulation by different redox-active compounds, such as glutathione. However, it is yet to be determined whether this process occurs in vivo. Wheat CA1Pase heterologously expressed in E. coli is also able to dephosphorylate the RuBisCO inhibitor D-glycero-2,3-diulose-1,5-bisphosphate.
== History == Pyridoxine was discovered in 1934, isolated in 1938, and first made in 1939. It is on the World Health Organization's List of Essential Medicines. Pyridoxine is available both as a generic medication and over the counter product. Foods, such as breakfast cereal have pyridoxine added in some countries.
Sources: en.wikipedia.org
Aquileia virtual tour (Italian Landmarks) Pre-Roman and Celtic Aquileia Explore the Archaeological Area and the Patriarchal Basilica of Aquileia in the UNESCO collection on Google Arts and Culture Aquileia featured on 10 Euro Italian Coin
Endospore staining is used to identify the presence or absence of endospores, which make bacteria very difficult to kill. Bacterial spores have proven to be difficult to stain as they are not permeable to aqueous dye reagents. Endospore staining is particularly useful for identifying endospore-forming bacterial pathogens such as Clostridioides difficile. Prior to the development of more efficient methods, this stain was performed using the Wirtz method with heat fixation and counterstain. Through the use of malachite green and a diluted ratio of carbol fuchsin, fixing bacteria in osmic acid was a great way to ensure no blending of dyes. However, newly revised staining methods have significantly decreased the time it takes to create these stains. This revision included substitution of carbol fuchsin with aqueous Safranin paired with a newly diluted 5% formula of malachite green. This new and improved composition of stains was performed in the same way as before with the use of heat fixation, rinsing, and blotting dry for later examination. Upon examination, all endospore forming bacteria will be stained green accompanied by all other cells appearing red.
==== Mild phenotype ==== There is an ultra-rare mild phenotype caused by recessive heterozygous alleles in the PYGM gene, where one allele is a common exon mutation and the other allele is an ultra-rare intronic mutation. It can also be caused by recessive homozygous intronic mutations. These intronic mutations result in a milder phenotype compared to the classic phenotype of McArdle disease. There is residual myophosphorylase activity, between 1-2% residual activity compared to unaffected individuals. This results in greater exercise capacity compared to classic phenotype McArdle individuals, particularly for sustained aerobic activity, but the capacity was still below that of unaffected individuals. In this mild phenotype, since their early teens, they did experience cramping and premature muscle fatigue during sudden vigorous exercise and prolonged isometric exercise; however, due to their less diminished capacity for aerobic activity, they were able to keep up with their peers in sports and everyday activities. As of 2009, there have been 3 reported cases of non-related individuals, a reported Druze family of consanguineous (related) individuals and 9 reported cases in two Finnish families.
== External links == Book page on McSweeny's Archived 2013-05-14 at the Wayback Machine Dani Shapiro on Half a Life in The New York Times Book Review Strauss with Sam Tanenhaus of The New York Times Book Review Archived 2012-04-05 at the Wayback Machine Strauss and "Guilty as Not Charged" on This American Life Poets & Writers on Darin Strauss and Half a Life
=== Oxygen therapy === Oxygen therapy at home is recommended in those with significantly low oxygen levels. Oxygen therapy in ILD is associated with improvements in quality of life but reductions in mortality are uncertain. Long-term oxygen therapy can be beneficial to people with ILD and hypoxemia to enhance gas exchange, lessen dyspnea, and increase physical activity.
Sources: en.wikipedia.org
Risk factors for complications and death include age, hemodynamic parameters (such as heart failure, cardiac arrest on admission, systolic blood pressure, or Killip class of two or greater), ST-segment deviation, diabetes, serum creatinine, peripheral vascular disease, and elevation of cardiac markers.
== Education == He studied chemistry at the Eötvös Loránd University (Budapest), where he graduated in 1973 and received a PhD in biochemistry in 1976. He worked as a postdoctoral research fellow at the University of California, San Francisco in 1978-1979.
=== Flexible rechargeable battery electrode === Graphene oxide has been demonstrated as a flexible free-standing battery anode material for room temperature lithium-ion and sodium-ion batteries. It is also being studied as a high surface area conducting agent in lithium-sulfur battery cathodes. The functional groups on graphene oxide can serve as sites for chemical modification and immobilization of active species. This approach allows for the creation of hybrid architectures for electrode materials. Recent examples of this have been implemented in lithium-ion batteries, which are known for being rechargeable at the cost of low capacity limits. Graphene oxide-based composites functionalized with metal oxides and sulfides have been shown in recent research to induce enhanced battery performance. This has similarly been adapted into applications in supercapacitors, since the electronic properties of graphene oxide allow it to bypass some of the more prevalent restrictions of typical transition metal oxide electrodes. Research in this field is developing, with additional exploration into methods involving nitrogen doping and pH adjustment to improve capacitance. Additionally, research into reduced graphene oxide sheets, which display superior electronic properties akin to pure graphene, is currently being explored. Reduced graphene oxide greatly increases the conductivity and efficiency, while sacrificing some flexibility and structural integrity.
2024 Conservative Party leadership election: Nominations open for the first round of the leadership election. July 2024 Welsh Labour leadership election: Eluned Morgan is elected unopposed as the new leader of Welsh Labour after nominations close at midday. The Senedd will be recalled on 6 August to choose a new First Minister of Wales following the resignation of Vaughan Gething and the subsequent Welsh Labour leadership election. 25 July – Conservative Party leadership election: Tom Tugendhat and Robert Jenrick enter the race to become the next Conservative leader. 26 July – Labour peer Lord Falconer introduces the Assisted Dying Bill into the House of Lords. The bill would allow anyone with a terminal illness and less than six months left to live to get medical assistance to end their life. Following a critical report on the Care Quality Commission, Health Secretary Wes Streeting describes the body as not fit for purpose. Conservative Party leadership election: Former Work and Pensions Secretary Mel Stride becomes the fourth candidate to announce his intention to run for the Conservative Party leadership election. 27 July – Conservative Party leadership election: Priti Patel becomes the fifth candidate to put their name forward for the election, standing as a unity candidate. 28 July – Labour accuses the previous Conservative government of "covering up" "catastrophic" problems in the public sector and creating a multi-billion pound gap in public finances.
Sources: en.wikipedia.org
No major medicines regulator appears to have approved AOD-9604 for human therapeutic use. It has been studied in clinical trials, but those programs did not result in a marketed drug.
It became prominent during a 2013 Australian sports investigation that examined whether it was a prohibited growth-hormone-related substance. Subsequent interpretations and list updates have varied, so current rules should be checked directly.
Published summaries generally report limited or inconsistent weight-loss effects, and complete trial data are not widely available. The studies were not sufficient to establish it as an effective obesity treatment.
No. It is not approved as a therapeutic drug by major regulators. It is sold for research purposes in many settings, which is not the same as clinical approval.